The 5th Annual Psychedelic Therapeutics and Drug Development Conference is dedicated to the research and development of psychedelics for various health conditions.
The 5th Annual Psychedelic Therapeutics and Drug Development Conference covers topics such as:
- Risk Evaluation and Mitigation Strategy (REMS)
- Clinical trial design
- Practical use/indications/
- Abuse potential
- Targets for novel drug development
- DEA licensure and policy considerations
- Second generation psychedelic drug design
- Dosage (micro/low/high)
- Toxicology studies and considerations
- FDA regulatory guidance
The 5th Annual Psychedelic Therapeutics and Drug Development Conference brings together:
- Vice Presidents
- Chief Executive Officers
- Business Development Professionals
- Chief Medical Officers
- Research Scientists
- Regulatory Affairs Professionals
- Clinical Development Professionals
- R&D Professionals
- Investigators
- Licensing Professionals
- Chemists
- Medical Chemists
- Scientists
- Pharmacists
- Project Managers
- Study Managers
- Professors
- Scientific Officers
- Health Care Practitioners
- Ph.D./Pharm.D. Students
- Investors
- Program Officers
- Medical Directors
- Analysts
The 5th Annual Psychedelic Therapeutics and Drug Development Conference might be held in United States in May 2025.
